A citation-based method for searching scientific literature

The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing.
Maria Elisa Mancuso, Johnny N Mahlangu, Steven W Pipe. Lancet 2021
Times Cited: 25



Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies.
Michael U Callaghan, Claude Negrier, Ido Paz-Priel, Tiffany Chang, Sammy Chebon, Michaela Lehle, Johnny Mahlangu, Guy Young, Rebecca Kruse-Jarres, Maria Elisa Mancuso, Markus Niggli, Monet Howard, Nives Selak Bienz, Midori Shima, Victor Jiménez-Yuste, Christophe Schmitt, Elina Asikanius, Gallia G Levy, Steven W Pipe, Johannes Oldenburg. Blood 2021
Times Cited: 31




List of shared articles



Times cited

An update of the current pharmacotherapeutic armamentarium for hemophilia A.
Johnny Mahlangu. Expert Opin Pharmacother 2022
1

Managing invasive procedures in haemophilia patients with limited resources, extended half-life concentrates or non-replacement therapies in 2022.
Maria Elisa Mancuso, Shashikant Apte, Cedric Hermans. Haemophilia 2022
0

Towards novel treatment options in von Willebrand disease.
Peter J Lenting, Claire Kizlik-Manson, Caterina Casari. Haemophilia 2022
0

Impact of novel hemophilia therapies around the world.
Margareth C Ozelo, Gabriela G Yamaguti-Hayakawa. Res Pract Thromb Haemost 2022
1

Next generation FVIII mimetic bispecific antibody for hemophilia A.
Jan Voorberg, Tim Postmus, Saskia Schols. J Thromb Haemost 2022
0

Current therapeutic approaches in the management of hemophilia-a consensus view by the Romanian Society of Hematology.
Ionut Hotea, Melen Brinza, Cristina Blag, Alina-Andreea Zimta, Noemi Dirzu, Corina Burzo, Ioana Rus, Dragos Apostu, Horea Benea, Mirela Marian,[...]. Ann Transl Med 2021
0


Longstocking, LLC. © 2021
Home | About Us | FAQs | Terms & Privacy